Investors

Press Releases

Propanc Successfully Completes Low Dose Group for GLP-Compliant 28-Day Repeat-Dose Toxicity Study

Feb 14, 2017

Propanc Provides Progress Update on Additional Patent Applications

Jan 24, 2017

Propanc Receives Allowance of Key Patent Application for Method of Treating Solid Tumors in the US

Jan 11, 2017

Propanc Provides Shareholder Update and Forecast for 2017

Jan 4, 2017

Propanc Commences GLP-Compliant 28-Day Repeat-Dose Toxicity Study

Dec 22, 2016

Propanc Health Group Presentation Now Available for On-Demand Viewing

Dec 5, 2016

Propanc Health Group Corporation to Webcast, Live, at VirtualInvestorConferences.com December 1

Nov 22, 2016

Propanc Files Application for Orphan Medicinal Product Designation in the EU for Ovarian Cancer

Nov 1, 2016

Propanc Completes Pivotal 28 Day Toxicokinetic Study for Lead Product PRP

Oct 25, 2016

Propanc Health Group Corporation Presentation Now Available for On-Demand Viewing

Sep 14, 2016

« Previous
1
2
3
4
5
6
7
8
9
10
Next »